Roche receives FDA clearance for additional Alzheimer’s

Roche receives FDA clearance for additional Alzheimer’s disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making

Roche, a leading biotechnology company, has obtained clearance from the U.S. Food and Drug Administration (FDA) for other Alzheimer’s disease Cerebrospinal Fluid (CSF) assays. The newly cleared assays, known as Elecsys tTau/Abeta42 ratio, are crucial in enabling timely diagnosis and facilitating treatment decisions for Alzheimer’s disease. The Elecsys tTau/Abeta42 ratio is designed to assist clinicians…

Parkinson's disease

Michael J. Fox Foundation Funds Research on a Potential Parkinson’s Biomarker

Introduction:  Parkinson’s disease is a progressive neurological disorder affecting millions worldwide. It is characterized by tremors, stiffness, and impaired movement, among other symptoms. Despite decades of research, there is currently no cure for Parkinson’s disease, and limited treatment options are available to patients. However, recent advances in biomarker research offer hope for earlier detection and…

Neurodex Presents Breakthrough Research on Exosomes for Neurodegenerative Disease Diagnosis at 'Extracellular Vesicles: Friends and Foes II' Congress

NeuroDex Presents Breakthrough Research on Exosomes for Neurodegenerative Disease Diagnosis at ‘Extracellular Vesicles: Friends and Foes II’ Congress

Neurodegenerative diseases Neurodegenerative diseases are a complex and growing public health concern. These conditions, including Alzheimer’s disease, Parkinson’s disease, and Lewy body dementia, can cause significant disability and reduced quality of life. Unfortunately, diagnosing these diseases can be challenging, with current diagnostic methods often requiring invasive procedures, such as brain imaging or lumbar puncture. Neurodex…